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ABSTRACT
HTLV-1 is estimated to affect ~20 million people worldwide and in ~5% of carriers 
it produces Adult T-Cell Leukemia/Lymphoma (ATLL), which can often masquerade 
and present with classic erythematous pruritic patches and plaques that are typically 
seen in Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most recognized 
variants of Cutaneous T-Cell Lymphomas (CTCL). For many years the role of HTLV-
1 in the pathogenesis of MF/SS has been hotly debated. In this study we analyzed 
CTCL vs. HTLV-1+ leukemic cells. We performed G-banding/spectral karyotyping, 
extensive gene expression analysis, TP53 sequencing in the 11 patient-derived HTLV-
1+ (MJ and Hut102) vs. HTLV-1- (Myla, Mac2a, PB2B, HH, H9, Hut78, SZ4, Sez4 and 
SeAx) CTCL cell lines. We further tested drug sensitivities to commonly used CTCL 
therapies and studied the ability of these cells to produce subcutaneous xenograft 
tumors in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. Our work demonstrates that unlike 
classic advanced MF/SS cells that acquire many ongoing balanced and unbalanced 
chromosomal translocations, HTLV-1+ CTCL leukemia cells are diploid and exhibit 
only a minimal number of non-specific chromosomal alterations. Our results indicate 
that HTLV-1 virus is likely not involved in the pathogenesis of classic MF/SS since it 
drives a very different pathway of lymphomagenesis based on our findings in these 
cells. This study also provides for the first time a comprehensive characterization of 
the CTCL cells with respect to gene expression profiling, TP53 mutation status, ability 
to produce tumors in mice and response to commonly used therapies.
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INTRODUCTION
Viruses are known to cause a number of human 
cancers, where Human Papilloma Virus (HPV), Human 
Herpesvirus 8 (HHV8) and Merkel Cell Polyomavirus 
were shown to cause Squamous Cell, Kaposi Sarcomas 
and Merkel Cell cancers, respectively. Similarly, Epstein-
Barr Virus (EBV) and Human T-Cell Lymphotropic Virus 
Type 1 (HTLV-1) were implicated as causes for a number 
of hematologic malignancies [1-3], where specifically 
HTLV-1 is known to cause Adult T-Cell Leukemia/
Lymphoma (ATLL), a WHO recognized variant of 
Cutaneous T-Cell Lymphoma (CTCL)[4, 5]. It is estimated 
that ~20 million people are infected with HTLV-1 around 
the world. This virus is prevalent in Central and West 
Africa, in the Caribbean, in Central and South America, in 
native populations in Canada, and among intravenous drug 
users in the United States [6].
Cutaneous T-Cell Lymphoma (CTCL) is the most 
common lymphoma of the skin [7]. Most CTCL variants 
(with a notable exception of ATLL and Extranodal NK/T-
cell lymphoma, nasal type) are not caused by an HTLV-1 
or another virus. CTCL was reported to be more common 
in HIV+ individuals [7-9]. Mycosis Fungoides (MF), 
its leukemic form, Sézary Syndrome (SS), and primary 
cutaneous anaplastic large cell lymphoma (cALCL) are 
the most common forms and account for ~80% of all 
CTCL [10].
MF typically presents with erythematous patches and 
plaques on the trunk following a bathing suit distribution, 
but as the disease progresses skin involvement can 
become confluent and patients can develop erythrodermic 
disease. MF can involve skin, lymph nodes, blood, bone 
marrow and visceral organs. SS is characterized by a 
triad of erythroderma, lymphadenopathy and detection of 
malignant T cells with cerebriform nuclei on a peripheral 
blood smear [5].
Before, SS was viewed as being on the same 
continuum with MF and was mostly regarded as an 
aggressive leukemic form of MF. However, as highlighted 
recently, SS is now considered separate from MF and 
erythrodermic/leukemic MF [11]. SS typically arises de 
novo and evolves in a short time period, although some 
patients may have a prodrome of pruritus, erythema and 
nonspecific dermatitis [11, 12]. It also has a much worse 
overall prognosis than the leukemic MF. In Caucasians 
MF/SS primarily affect individuals over 55 years of 
age, while in African-Americans, Hispanics and Arabic 
individuals this disease presents at a significantly younger 
age [13-15].
HTLV-1 in ~5% of carriers produces ATLL, which 
can have variable presentations and can often masquerade 
and present with classic MF-like erythematous pruritic 
patches and plaques. This can lead to misdiagnosis of 
Mycosis Fungoides. In fact, in two high profile reports 
published in Science and PNAS journals, two patients (a 50 
year-old Caucasian male form Boston, MA and a 28 year-
old African-American male presenting to the National 
Cancer Institute Veterans Administration hospital in 
Bethesda, MD) were diagnosed with “advanced Mycosis 
Fungoides” and have provided critical samples to establish 
MJ and Hut102 CTCL cell lines, respectively. These cell 
lines were later found to harbor HTLV-1 virus and, hence 
likely represent ATLL, not Mycosis Fungoides. Despite 
that, on the American Tissue Culture Collection (ATCC) 
website MJ is listed as “Cutaneous T Cell Lymphoma; 
Mycosis Fungoides” cell line and Hut102 is listed as 
“Lymphoma; Mycosis Fungoides” and not ATLL cell line. 
HTLV-1 serologic screening plays a key role to establish 
the diagnosis of ATLL in patients and without this test 
distinguishing the two lymphomas in North America 
would be very challenging in the clinic. To further 
complicate these matters, MF can exhibit an identical 
clinical course as the smoldering, chronic, lymphoma and 
leukemic variants of ATLL.
Distinguishing these lymphomas and better 
understanding their biologic differences is not of mere 
academic interest since ATLL poses a much greater risk 
to patients than MF, and may require earlier initiation 
of multimodality chemotherapy treatments and/or bone 
marrow stem cell transplantation. In addition, even in 
healthy HTLV-1 carriers impaired immune responses 
against EBV have been observed [16]. One way the 
virus leads to immunodeficiency is by infecting CD8+ 
T-lymphocytes, which impairs their function [17]. At last, 
it is important to distinguish these cancers to appropriately 
council our patients about precautions to decrease the risk 
of HTLV-1 transmission. Hence, it is critical to better 
understand the fundamental differences between HTLV-1+ 
vs. HTLV-1- lymphomas/leukemias. The current study was 
designed to highlight key molecular differences between 
classic MF/SS disease and HTLV-1+ leukemias.
RESULTS
Patient-derived cells are indispensable and are 
routinely used as robust and reproducible models to study 
human cancers. For CTCL, in particular, 11 patient-
derived cell lines are available to study this malignancy 
[18-20]. As discussed in the introduction, two of the cell 
lines (MJ and Hut102) harbor HTLV-1 virus. Furthermore, 
these cell lines remain poorly characterized and it remains 
not well elucidated which cell lines represent Mycosis 
Fungoides vs. Sézary Syndrome variants of CTCL. First 
and foremost, we have reviewed the original publications 
describing these cell lines. A summary of data from 
these papers is presented in Supplementary Table 1 and 
in Supplementary Materials of this report. Based on 
the available description of these patients, it appears 
that MyLa cells represent advanced extensive Mycosis 
Fungoides skin disease, Mac2A and PB2B lines represent 
advanced CD30+ lymphoproliferative skin lymphoma, HH 
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cells represent aggressive leukemic MF, while SZ4/Sez4, 
Hut78/H9 and SeAx cells represent Sézary Syndrome. 
Notably, as discussed above, Hut102 and MJ cells were 
indicated to represent Mycosis Fungoides, but were found 
to have HTLV-1 virus.
Use of RT-PCR assay to detect HTLV-1 virus in 
patient-derived cell lines
First and foremost, we used the previously 
described RT-PCR assay that is based on the detection of 
expression of Tax, Gag, Pol, Env and pX genes to identify 
which cells harbor HTLV-1 virus [21, 22]. This analysis 
demonstrated that out of 11 tested cell lines only MJ and 
Hut102 cells expressed these genes and are infected by 
HTLV-1 (Supplementary Figure 1). Importantly, this assay 
confirmed that Myla, Mac2a, PB2B, HH, H9, Hut78, SZ4, 
Sez4 and SeAx cells are HTLV-1 negative.
Structural karyotype analysis of the 11 patient-
derived cell lines
A number of important chromosomal alterations 
were reported in MF and SS patients with a number of 
important differences documented between MF and SS 
[23-28]. Hence, we wanted to perform G-band analysis 
and spectral karyotyping in our panel of CTCL cell lines. 
For each cell line we analyzed five cells by spectral 
karyotyping. This analysis revealed that all CTCL 
cell lines except the HTLV-1+ MJ and Hut102 cells 
demonstrate significant and ongoing genomic instability, 
where multiple different chromosomal changes are 
observed between these five cells within the same cell 
line. Summary of all karyotype data is presented in Table 
1, while detailed karyotype findings are presented in 
Supplementary Tables 2-3.
As alluded to above, one striking observation was 
that MyLa, PB2B, Mac2A, HH, Hut78, H9, SeAx, Sez4 
and SZ4 cells are mostly aneuploid and have a large 
number of alterations, while Hut102 and MJ HTLV-1+ 
cells are mostly diploid and have very few structural 
alterations. This dramatic difference highlights that even 
though MJ and Hut102 cells were derived from the “so 
called” MF CTCL patients they are vastly different form 
the classic MF/SS disease as represented by the other 9 
patient-derived cell lines. Indeed, previous reports did 
indicate a paucity of chromosomal alterations in ATLL 
patients [29, 30]
Next, based on this analysis we wanted to identify 
chromosomal abnormalities that are common for a given 
cell line and, more importantly, determine chromosomal 
alterations that are seen across multiple cell lines. These 
findings are presented in Supplementary Tables 2-3. These 
results demonstrate that, as expected, H9 and Hut78 (H9 
is a clonal line derived from Hut78) are almost identical 
structurally based on the number of shared chromosomal 
aberrations. Similarly, PB2B and Mac2A have a very 
similar number and types of chromosomal aberrations, 
which highlights that they represent the same clinical 
disease, but at different time points, as indicated in the 
original report [31, 32]. Notably, this analysis further 
confirms that, indeed, these biopsied skin tumors in this 
patient were caused by the same T cell clone [31, 32]. 
Also, our karyotype analysis confirms that SZ4 and 
Sez4 are essentially the same cell line that at some point 
acquired different names (Supplementary Tables 2-3).
Karyotype comparison of cell lines and human 
patient data
As demonstrated by the above analysis, 9 patient 
derived MF/SS cell lines have numerous chromosomal 
abnormalities and exhibit ongoing genomic instability, as 
highlighted by many changes that are seen sporadically 
in different cells within the same cell line (Table 1). In 
contrast, this was not seen in MJ and Hut102 HTLV-1+ 
cells. One question emerges is whether these structural 
findings reflect the clinical disease that is observed in 
MF/SS patients? Furthermore, it is recognized that certain 
structural chromosomal aberrations are more common 
in MF than SS. Can the presence or absence of these 
chromosomal aberrations help define cell lines as being 
representative of MF skin, lymph node vs. SS blood/
leukemic disease?
To answer these questions we compared our 
karyotype cell line findings to karyotype analysis of 
patients that were described in 15 seminal manuscripts 
[23-27, 33-42]. The number of selected papers is not 
exhaustive, but provides a broad representation of 
karyotype anomalies seen in MF and SS patients. Our 
detailed findings are presented in Supplementary Table 4. 
From this analysis it is evident that, like patient-derived 
cell lines, MF and SS patients universally exhibit a great 
number of chromosomal gains, losses, balanced and 
unbalanced translocations and other structural aberrations. 
This analysis demonstrates striking disease heterogeneity, 
where only few chromosomal alterations were noted 
across multiple studies (e.g., loss of 10q24, 9p21 etc.), 
while most chromosomal alteration are only reported to 
occur sporadically [23-28].
Notably, every time an aberration was seen in MF/
SS patients, aberrations in the same regions were also 
observed in the studied patient-derived cells. Importantly, 
chromosomal losses in 1p36.1, 9p21, 13q14 and 16q24 
regions that were commonly seen in MF and SS patients 
were also present in 2-5 out of 11 studied CTCL cell lines 
(Supplementary Table 4). Interestingly, losses and gains 
that were seen in 10q24 region in SS patients were also 
observed in blood-derived SeAx, Sez4, SZ4, H9, Hut78 
and HH cells, but not in skin-derived MF MyLa, Mac2A 
and PB2B cells. Hence, loss of 10q24 region could be a 
structural change marker indicative of a leukemic disease. 
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Table 1: Results of G band and spectral karyotyping analyses for the 11 patient-derived CTCL cell lines 
Cell line G to Sky karyotype findings
MyLa
46~48,XY,der(1)(1pter→1q32:)[5],der(1)t(1;15)(p36.2~36.3;q15)[5],der(2)t(2;14)
(q32~33;q12~13)[5],t(4;5)(q13;q14)[5], der(5)t(5;?)(q35;?)[5], del(6)(q15q23)[5], del(7)(p15)
[5],del(9)(p21)[5],der(10)t(10;13)(p14;q13)[5], der(13)t(13;14)(q33;q21)[5],der(13)t(13;16)
(q14;?q23)[5], der(14)(2pter→2p13::14p12→14q12~13::2q32~33→2qter)[5], der(14)t(14;18)
(q22;q22)[4],der(15)t(1;15)(q32;q15)[5],+17 [5], der(18)t(18;?19)(q23;p13.1~13.2)[5],der(19)
t(?11;19)(?;p13.1~13.2)[5], der(20)t(20;?)(q13.3;?)[5], der(21)t(20;21)(?p11.2;q22.3)[5],?psu 
dic(16;22)(p10;p13)[5][cp5]
Mac2A
43~44,X,-Y [5],t(3;7)(q22~23;q21.2~22)[5],del(6)(q15)[5], der(6)t(6;22)(p21.1~21.2;q11.1)
[5], der(8)(?9?→?9?::8p22→8qter)[5], der(9)(8pter→8p22::9p24→9q34::?5?→?5?)[4],der(10)
(?acro-p::10q10→10qter)[5],der(10)(10pter→10q2?6::10q2?6→10q2?1::12q21→12qter)[5], 
der(11)t(11;14)(q22;q13~21)[5], del(12)(q11q13)[5],-14 [5], der(15)t(2;15)(p11.2;p12)[5], del(16)
(q11.2q22)[5], ?dup(16)(q21q24)[5], der(20)(:20?q13.1→20?q13.1::20p13→20q?13.1::20q?13.
1→20qter)[5], -22 [5],der(22)(6?pter→6?p21.3::22q10→22q11.2::22q13.1→22qter)[5], +der(?)
(?acro-p→?cen::?cen→?acro-p)[4][cp5]
PB2B
45,X,-Y [5],t(1;17)(p34.3~35;q21)[4],t(2;10)(p24;q25.3~26.1)[5], der(3)t(1;3)(q12~21;q24)
[2] or der(3)(3pter→3q24:)[3], +der(5)(:5q10→5qter)[5], der(5;6)(5pter→5p10::6q10→6q15:)
[5],inv(7)(p11.2p22)[5],
der(8)(?9?→?9?::8p22→8qter)[5], der(9)(8pter→8p22::9p24→9q22::3q23→3qter)[5], der(10)
t(6;10)(?;q10)[5],del(11)(p15.2~15.4)[4], der(12)(12pter→12q11::12q13→12qter)[5], der(12)
(12pter→12q13::12q13→12q11::12q13→12qter)[4], der(15)t(2;15)(p11.2;p12)[5],del(16)
(q11.2q22)[5], der(18)t(6;18)(p12;p11.3)[5],der(18)t(12;18)(?;q22)[4], der(20)(:20?q13.1→20
?q13.1::20p13→20q?13.1::20q?13.1→20qter)[5], der(21)t(9;21)(q22;p12)[5],der(22)t(14;22)
(q22;q10)[5][cp5]
HH
44~45,X,-Y [5],?del(2)(q3?2q3?3)[5], der(3)t(2;3)(p?14~21;p25~26)[5], der(3)
(3pter→3p10::12q21→12qter)[4], der(4) (4pter→4q21::4q?→4q?::4q21→4q31::4q?→4q?::4q3
1→4q3?3::1p35~36.1→1pter)[5], der(5)(10qter→10q24::9q34→9q13::5p15→5qter)[5],t(6;14)
(q23~24;q23~24)[5],+8 [5], der(9)(9pter→9p10::?acro-p)[5], der(10)(10pter→10q24:)[5],der(12)
(12pter→12q21::3q11.2→3qter)[5], der(14)(::14q13→14q10::14q13→14qter)[5],-15 [5], der(17)
t(?11;17)(q23;q25)[5],der(18)t(3;18)(q24;q22)[5][cp5]
SZ4
79~81<4n>,X or XX,+der(X)(Xpter→Xq23~24:)[2] or der(X)(Xpter→Xq23~24:)[1] or 
der(X;20)(p10;q10)[2],-X [5],-X [5], +1 [5],der(1)(3pter→3p21::?→?::3p21→3p13~14::1p31→1
q42::8p21→8pter)[5], der(1)(6qter→6q23::1p32~34→1qter)[5],
psu dic(1;16)(16pter→16q24::1q22~25→1q10::1q10→1qter)[5], t(1;11;8)(q42;q23;p21)
[5], der(3)t(3;6)(q12~13;?)[5], der(3;10)(q10;q10)[2],der(4)t(4;20)(q33;?q13.1)[5], ?inv(4)
(q33q35)[5],psu dic(4;21)(q10;p12~13)[5], der(5)(5pter→5p10::5q35→5q31::1?→1?::7
?→7?::5q35→5q31:)[4], der(6)(6pter→6p21.3::6p21.1→6q23~24::1p34→1pter)x2 [5], 
t(6;11)(q16~21;q21~22)[5],-7 [5],der(7)t(7;20)(q22;p11.1~11.2)[3],-8 [5],ins(8;18)(q11.2;?)
[2],der(9)t(9;14)(p13~22;q13)x2 [5], der(10)(10pter→10q24:)x1 [2] or x2 [3], der(10;17)
(17pter→17p10::10q10→10q24:)[2], der(11)(:14q?32→14q?24::11p15→11q21~22:)[5],-12 [5],-
13 [3], der(13)(:13q?31→13q?14::13p12→13qter)[5], -14 [5],-14 [5],der(14)t(7;14)(p13~15;q10)
[5], der(15)(10qter→10q24::15p12→15qter)[5], del(16)(q11.1)[3], der(17)(17qter→17q10::17q
10→17q25::?3?q13.3→?3q21:)[2] or der(17)(17pter→17q25::3?q13.3→3q26::13q31→13qter)
[3], i(17)(q10)[3],+der(18)(acro-p::18?→18?::7q22→7qter)[3], der(18) (8qter→8q11.2::18?p11
.3→18?q12::Xq2?8→Xq2?3~2?4::3q13.2~13.3→3qter)[3], der(18)t(8;18)(q11.2;p11.3)[5], -19 
[5],der(19)t(7;19)(p11;q13.4)[4], +21 [5],der(21)t(9;21)(p22;q22)x2 [5],-22 [5], +der(?)(acro-
p::8?q13→8?q22:)[5][cp5]
(Continued)
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Cell line G to Sky karyotype findings
Sez4
77~80<3n>,XX [2] or t(X;X)(p22.2;p22.3)[2],-?X [5],+psu dic(1;16)(16pter→16q24::1q22~25
→1q10::1q10→1qter)[5], der(1)(3pter→3p21::?→?::3p21→3p13~14::1p31→1qter)[5], der(1)
(1pter→1q42::8p21→8pter)[2] or t(1;11;8)(q42;q23;p21)[2], +2 [4],+der(3)t(3;6)(q12~13;?)
[5],+der(4)t(4;7)(q23~27;q22)[2] or der(4)t(4;7)(q23~27;q22)[2],der(4)t(4;10)(p15;q25)
[3],+der(5) (5pter→5p10::5q35→5q31::1?→1?::7?→7?::5q35→5q31:)[5], der(6)(6pter→6p21.
3::6p21.1→6q23~24::1p34→1pter)[5], der(6)(6pter→6p21.3::6p21.1→6p10::7p13→7pter)[2], 
t(6;11)(q16~21;q21~22)[5], -7 [3],i(7)(q10)[2],der(8)t(8;11)(p21;q23)[2], +del(9)(q12)[5],der(9)
t(9;14)(p13~22;q13)x2 [5], +10 [2] or +der(10)t(4;10)(q28;q25)[3],der(10)(10pter→10q24:)x2 
[5], +der(11)(:14q?32→14q?24::11p15→11q21~22:)[3] or der(11)(:14q?32→14q?24::11p15→1
1q21~22:)[1], der(13)(:13q?31→13q?14::13p12→13qter)[3],
-14 [5],der(15)(10qter→10q24::15p12→15qter)[5], del(16)(q11.1)[5],+i(17)(q10)[4] or i(17)
(q10)[1],der(18)t(8;18)(q11.2;p11.3)x2 [5], der(19)t(7;19)(p11;q13.4)[5],+20 [5], +der(21)t(9;21)
(p22;q22)x2 [5],+der(?)(acro-p::8?q13→8?q22:)[5][cp5]
SeAx
64~71<3n>,X,-X [5],der(X;16)(q10;p10)[5], +der(1)t(1;2)(p10;?)x1 [1] or x2 [3], der(1)
(:1q21→1p36.1::1q21→1qter)[5],der(1)(12qter→12q21~23::1p21→1q21:)[5],i(1)(q10)[5], 
+der(2;19)(6qter→6q22::2?→2?::19q10→19qter)[3] or der(2;19)(6qter→6q22::2?→2?::19q10→
19qter)[2],
der(2)(6qter→6q22::2?→2?::16q11.2~13→16qter)[4], der(2)(11qter→11q14~21::2?
→2?::2?p25→2?qter)x1 [2] or x2 [3], +der(3;17)(p10;p10)[4] or der(3;17)(p10;p10)
[1], der(3)t(X;3)(p11.4~21;q23~24)[4], der(3)(3pter→3q12::3?→3?::?11 or 17?→?11 or 
17?::3?→3?::9q13~21→9qter)[5],
-4 [5],der(4)t(1;4)(p36.1;p16)[4],+der(5)t(5;8)(p13;p22~23)[4],
+der(6)(6pter→6q10::6?→6?::2q22~23→2qter)[4] or der(6)(6pter→6q10::6?→6?::2q22~23→2
qter)[1],
der(6)(6pter→6q22:)x1 [1] or x2 [4],der(6)(6pter→6q22::2?→2?::6?→6?::16?→16?)[5], der(7)
(7pter→7q32::10q22→10q24::5p13→5pter)[5],der(8)t(8;10)(p22~23;q24)x3 [5], -9 [5], der(10)
t(5;10)(p13;q24)x2 [5], der(10)(10pter→10q24:)[4], der(11)t(2;11)(?;q14~21)x2 [5],der(12)
t(10;12)(?;p12~13)[5], -13 [5],der(14)t(12;14)(p12~13;p12)[4],+der(17)t(15;17)(?;p10)[4] or 
der(17)t(15;17)(?;p10)[1],der(17)t(3;17)(q12;q10)x2 [5], -18 [5],+20 [4][cp5]
Hut78
71~75<3n>,-Y [5],t(X;13)(p11.2~11.4;q14)x1 [1] or x2 [4],+der(2;20)(p10;p10)[5], der(2)(2pte
r→2q21::2?q31→2?q33::8q24.1→8qter)[5],+3 [5], der(3)(3pter→3q29::10q24→10qter)x1 [1] 
or x2 [4], +?4 [5],?4 [5], der(4)(4pter→4p?14::4?q21→4?p14::4?q25→4?q21::16p?11.1→16p?
13.3::13q14→13qter)[5], der(4) (4pter→4p?14::4?q21→4?p14::4?q25→4?q21::16p?11.1→16
p?13.1::6?→6?::11p11.2→11pter)[5], -5 [3],der(5)t(5;8)(?;?)[2], t(5;6)(p10;p10)x2 [5], +der(6) 
(4qter→4q21~24::6?p21→6?q13::6?q23→6qter)x2 [5], +der(7)t(7;8)(q11.2;q24.1)[5],der(7)
(10?→10?::7p14~15→7qter)x2 [5],
der(8)(?5?→?5?::8q10→8q22~24.1::5?q33→5?qter)[2] or der(8;20)(20qter→20q10::8q10→8q2
2~24.1::5?q33→5?qter)[2],
-9 [5], der(9)(Y?→Y?::9p21~22→9qter)x2 [5], der(10)t(7;10)(q11.2;q22.2~22.3)[5], der(10)
(10pter→10q24:)[5],
der(11)(?16?→?16?::11?p12~14→11p10::11q21→11qter)[3],?del(12)(p13)[2],-13 [4],+14 
[5],?del(14)(q?11.2q?24)x2 [5],+15 [3], -16 [5], +17 [5],+der(18)t(18;20)(?q11.2;?p11.2)
[2],der(18)t(2;18)(?p22~23;p11.2~11.3)x1 [1] or x2 [4],i(18)(p10)[4], +der(19)t(19;20)
(q13.?3;q11.2)[5], der(19)t(19;20)(q13.?3;q11.2)[5],der(19;22)(q10;q10)x2 [5],+del(20)
(q11.2q13.1)[4], del(20)(q11.2q13.1)[1],+der(20;21)(20pter→20p10::21q10→21q22::8?q24.1→8
?qter)[4], der(20)(:9p11→9p24::20p13→20qter)x2 [5], der(20)(20pter→20q10::20?→20?::20q12
→20qter)[2], der(21)(11qter→11q13~14::21q10→21qter)[4][cp5]
(Continued)
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Importantly, this analysis indicates that chromosomal 
aberrations (number of abnormalities and their nature) 
seen in cell lines are representative of karyotype changes 
that are routinely observed in MF/SS patients.
In summary, 9 MF/SS cell lines appear to represent 
six clinical CTLC cases: 1) MyLa, 2) Mac2A/PB2B, 
3) HH, 4) Hut78/H9, 5) SeAx and 6) Sez4/SZ4, while 
Hut102 and MJ genetically differ greatly from classic MF/
SS disease and represent ATLL.
Gene expression changes and clustering of the 
MF/SS cell lines
In recent years a number of studies performed 
analysis of gene expression in MF/SS patients in order 
to identify novel diagnostic/prognostic markers and to 
better understand oncogenes and tumor suppressor genes 
involved in lymphomagenesis [18-20, 43-50]. This work 
highlighted many genes, whose expression is believed to 
be important in CTCL (e.g., TOX, GTSF1, LCK, FYB, 
CCR4, ITK, CD30/TNFRSF8, etc.), which are described 
in the supplementary tables of our previous reports [18, 
20, 44, 50]. These genes were time and again validated 
across multiple studies to play an important role in CTCL 
pathogenesis. Based on our previous work, we have 
performed gene expression analysis of the selected 107 
selected genes in the 11 patient-derived cell lines and have 
performed unsupervised clustering analysis based on these 
expression findings. MJ cells were used as a reference 
since they showed detectable expression for all 107 genes.
This clustering analysis separated all cell lines into 
two clusters based on their gene expression profile (Figure 
1). Cluster 1 included HH, MyLa, PB2B and Mac2A 
cells. Importantly, as highlighted in Supplementary Table 
1/Supplementary Materials of this report, all these cells 
were derived from MF patients, albeit most of them had 
a leukemic stage IV disease. Also, notably, within this 
cluster Mac2A and PB2B cells clustered together based 
on the similarities of their gene expression profiles. This is 
expected, since, as described above, these cells are derived 
from the same clone that produced different variants of 
CTCL within the same patient.
Cluster 2, on the other hand, contained all cell lines 
that were derived from Sézary Syndrome patients (Sez4, 
SZ4, SeAx, H9 and Hut78) and HTLV-1+ cells (MJ and 
Hut 102). Notably, these HTLV-1+ cells lines clustered 
together in cluster 2B and away from the other SS cells 
that together formed cluster 2A. Hut78 and H9 clustered 
together based on their gene expression patterns, as 
expected. Similarly, Sez4 and SZ4 cells clustered together 
and they were very similar to the SeAx cells based on the 
expression of the tested genes.
Hence, this clustering analysis confirms that MyLa, 
PB2B, Mac2A and HH represent Mycosis Fungoides on 
a molecular level, while SeAx, Sez4, SZ4, H9 and Hut78 
represent Sézary Syndrome. While, MJ and Hut102 
HTLV-1+ cells based on gene expression appear similar 
to the SS and not leukemic MF variant of CTCL, as 
highlighted by the karyotype analyses they truly do not 
represent either.
Cell line G to Sky karyotype findings
H9
60~70<3n>,-Y [5],der(X)t(X;13)(p11.2~11.4;q14)x2 [5],der(1)(1pter→1q31::1?→1?)[5], der(2)
(2pter→2q21::2?q31→2?q33::8q24.1→8qter)x2 [5], der(3)(3pter→3q29::10q24→10qter)x1 [1] 
or x2 [4], ?4 [5],?4 [2],der(4)(4pter→4q22~24::?6?→?6?)[2], der(4)(4pter→4p?14::4?q21→4?p1
4::4?q25→4?q21::16p?11.1→16p?13.3::13q14→13qter)[5],
t(5;6)(p10;p10)x1 [1] or x2 [4],der(5)(5pter→5p10::?acro-p)[2], +der(6)(4qter→4q21~24::6?p21
→6?q13::6?q23→6qter)x1 [1]or x2 [4], der(6)(:9p11→9p24::6p21.3→6qter)[5], +der(7)(7pter→
7p10::3q13.2→3q29::10q24→10qter)[5],
der(7)(10?→10?::7p14~15→7qter)x2 [5],der(7)(7pter→7q31~32::17?→17?)[5], der(8)t(?2;8)
(?;q24.1~24.2)[3],
-9 [5],der(9)(Y?→Y?::9p21~22→9qter)x1 [2] or x2 [3],
+der(10)(10pter→10q24:)[4] or der(10)(10pter→10q24:)[1], der(10)(6qter→6q21::10p11.2→10q
24::6q21→6qter)[3], der(10)t(7;10)(q11.2;q22.2~22.3)x2 [5], ?del(11)(q?13~14)x2 [5],-13 [5],
der(13)(10qter→10q24~25::2q33→2q14.3~21::13q10→13q14::Xp11.2~11.4→Xpter)[5],der(13)
t(X;13)(p11.2~11.4;q14)[4], ?del(14)(q?11.2q?24)[5],-15 [5],-16 [5],+17 [4], +der(18)t(15;18)
(q1?5;q10)[2],i(18)(q10)[4],t(18;18)(p10;p10)[4], +der(19)t(19;20)(q13.?3;q11.2)[5],t(19;20)
(q13.?3;q11.2)[5],der(19;22)(q10;q10)x2 [5],+der(20)t(6;20)(p21.3;p13)[3] or der(20)t(6;20)
(p21.3;p13)[1], der(20)(:9p11→9p24::20p13→20qter)[4], der(20)(20pter→20q10::20?→20?::20
q12→20qter)[4], der(21)(11qter→11q13~14::21q10→21qter)[4][cp5]
MJ 42~47,XY,der(17)t(2;17)(p11.2;q25)[5][cp5]
Hut102 46 or 92,XY or XXYY,der(6)(6pter→6q?21::6q?27→6q?21::6q?23→6q?21:)x1 [3] or x2 [2][cp5]
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Analysis of expression of specific poor vs. 
favorable markers in patient-derived CTCL cells
Further in-depth analysis of gene expression across 
the 11 cell lines highlights important downregulation of 
IFN-ɣ in MF/SS cells (Figure 2A). Also, SERPINB13 
favorable prognosis marker was downregulated in all 
cell lines (Figure 2B), therefore, pointing to the overall 
advanced disease nature of these cells. Notably, IL-12 is 
a key cytokine involved in promoting the Th1 immune 
response. CTCL is known to undergo a switch from the 
Th1 to Th2 immune response in advanced disease [19]. 
IL-12A was strongly expressed in MF cell lines (HH, 
MyLa, PB2B and Mac2A), but not in Sézary cell lines 
Figure 1: Unsupervised clustering analysis based on RT-PCR expression of 107 select genes in 11 patient-derived cell 
lines.
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(Sez4, SZ4, Hut78 or H9) with a notable exception of 
SeAx (Figure 2C). None of the cells expressed IL-12B 
(data not shown) and, hence, are not able to produce a 
functional IL-12 cytokine. These findings point to the 
advanced disease state of all tested cells, but suggest 
that MF cells incompletely lost their ability to express 
some of the components of the IL-12 machinery. Also, 
importantly, CD30 expression was detected in all cell 
lines, but was strongest in PB2B, Mac2A cells that were 
derived from a known CD30+ MF/ALCL, as well as in 
HH cells that were also derived from an advanced MF 
patient (Figure 2D).
On the other hand, IL-10 a T reg cytokine that 
is known to be expressed in advanced stages was 
undetectable in MF cells MyLa, HH, Mac2A and PB2B, 
but was expressed across a panel of Sézary cells, but 
Table 2: TP53 mutation status in patient-derived CTCL cell lines
Cell line TP53 Status
cDNA Protein Codon 72 MLPA
Allele 1 Allele 2 Allele 1 Allele 2
MyLa c.75-80 C>G + + + Arg/Arg Dup x1-11
Mac2A c.75-80 C>G + + + Arg/Arg Normal
PB2B c.75-80 C>G + + + Arg/Arg Normal
HH c.560-1G>A c.560-1G>A Splicing affected Splicing affected Arg/Arg Del x1-11/+
SeAx c.733G>A c.733G>A p.Gly245Ser p.Gly245Ser Arg/Arg Normal
SZ4 c.75-80 C>G c.75-80 C>G + + Arg/Arg Normal
Sez4 c.75-80 C>G c.75-80 C>G + + Arg/Arg Normal
Hut78 c.75-80 C>G c.75-80 C>G p.Arg196X p.Arg196X Arg/Arg Normal
c.586 C>T c.586 C>T
H9 c.75-80 C>G c.75-80 C>G + + Arg/Arg Normal
MJ c.75-80 C>G + + + Pro/Arg Normal
Hut102 c.75-80 C>G + + + Arg/Arg Normal
Table 3: Sensitivity (IC50) of the tested cell lines to the 3 commonly used systemic therapies in CTCL
A B C
Romidepsin Vorinostat Bexarotene
Cells IC50 (μM) Cells IC50 (μM) Cells IC50 (μM)
Sez4 0.14 Hut78 1.43 MJ 2.62
SeAx 0.14 H9 2.29 SeAx 9.92
H9 0.16 PB2B 4.90 Sez4 11.35
MyLa 0.26 SeAx 5.79 PB2B 13.03
HH 0.41 HH 29.59 HH 13.89
Mac2A 0.48 SZ4 30.30 MyLa 18.23
PB2B 0.73 MyLa 34.38 H9 23.72
Hut78 0.77 MJ 34.45 Hut102 28.06
MJ 2.97 Sez4 37.44 Mac2A 28.75
SZ4 3.03 Mac2A >40 SZ4 28.87
Hut102 >4 Hut102 >40 Hut78 35.10
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not HTLV-1+ cells (Figure 2E). Expression for a number 
of additional poor prognosis markers including ITK, 
AHI1, TRAF3IP, FYB, KIT, LCK and TBX3 was further 
upregulated preferentially in Sézary cells (Figures 2F-2H 
and Figure 3A-3D). GTSF1 poor prognosis marker cancer-
testis gene was previously shown to be strongly expressed 
in MF/SS patients [18, 20, 44, 47]. This gene was strongly 
expressed in all 9 tested CTCL cell lines and was only 
weakly expressed in HTLV-1+ cells.
These combined gene expression findings further 
corroborate our earlier conclusions and highlight that 
while all cells lines represent advanced CTCL disease, 
MyLa, PB2B/Mac2A, and HH represent Mycosis 
Fungoides, where PB2B, Mac2A and HH represent CD30+ 
MF and/or ALCL disease. On the other hand, SeAx, Sez4/
SZ4, Hut78/H9 represent Sézary syndrome. Hut102 and 
MJ cells show gene expression profile that is similar to 
Sézary Syndrome, but truly represent a leukemic form of 
ATLL.
TP53 mutation status in cell lines
TP53 mutations were previously reported to occur 
in advanced disease stages and were associated with 
poor survival in patients [51]. Hence, we performed the 
sequencing of the TP53 gene and identified that Sézary 
cells Hut78 and SeAx carry mutations of p53 (Table 
2). HH, advanced MF line, had a change that affects 
the splicing of the gene. The most common codon 
polymorphism (at 72nd codon) was Arg/Arg. Only MJ 
cells had a Pro/Arg polymporphism. MLPA analysis 
demonstrated duplication of the gene in MyLa and HH 
cells (Table 2).
Hut78 and its clonally derived variant, H9, had a 
nonsense mutation of p53 in exon 6. SeAx cells had 
a deleterious Gly245Ser mutation in exon 7. HH cells 
harbor a c560-1G>A mutation, which is predicted to affect 
splicing in intron 5 and lead to partial loss of function. 
Many cell lines had a silent c75–80C>G polymorphism in 
intron 2, which is predicted not to affect gene expression 
or function (Table 2).
These findings are consistent with the previous 
reports of TP53 mutations in advanced disease patients. 
Considering that all 9 CTCL cell lines represent advanced 
stages of CTCL, it is not surprising that a number of these 
cells (i.e., Hut78, H9, SeAx and HH) have mutated TP53. 
Notably, HTLV-1+ MJ and Hut102 cells had wild type 
TP53.
Testing cell line sensitivities to commonly used 
medication treatments in CTCL
Stage IIB-IVB MF patients that were refractory 
to two or more standard therapies demonstrated 
overall response rate of 45% or 55% with daily doses 
of bexarotene 300 or 650 mg/m2, respectively [52]. 
Histone deacetylase inhibitors (HDACs) on the other 
hand demonstrated partial response in 29.7% of patients 
with only 1 complete response for Vorinostat and 
36% response rate including 5 complete responses for 
Romidepsin [52]. Hence, we wanted to subject our cell 
lines to these treatments at various concentrations to 
determine their sensitivities (i.e., IC50) to Romidepsin, 
Vorinostat and Bexarotene. As demonstrated in Table 3, 
the 11 cell lines demonstrated different sensitivities to 
the tested treatments. Interestingly SeAx and PB2B cells 
were relatively sensitive to all three treatments, Hut78 
and H9 were sensitive to both HDAC inhibitors (i.e., 
Romidepsin and Vorinostat), while HTLV-1+ Hut102 and 
MJ cells were relatively resistant to the HDAC inhibitors 
at concentrations ≤40 μM.
Study of patient–derived cells in NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ mice
We then wanted to extend our molecular 
observations and correlate our findings clinically by 
implanting and growing these cell lines as subcutaneous 
Table 4: T-cell receptor beta and gamma clonality findings for the obtained xenograft tumor tissues
Cell line TCR gamma receptor TCR beta receptor
Vy-Jp Vy-Jy TCRB-A TCRB-B TCRB-C
MyLa --- +++ --- --- ---
PB2B +++ --- --- --- ---
HH +++ +++ --- + ---
Hut78 --- +++ --- --- +++
H9 +++ +++ --- --- +++
Hut102 --- +++ --- --- ---
MJ --- +++ --- --- ---
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xenograft tumors in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (also 
commonly referred to as NSG strain) mice. Previous 
reports demonstrated that these mice could serve as a 
powerful model to study CTCL pathogenesis [53]. As 
demonstrated in Figure 4A, 8/11 cell lines were able to 
produce tumors in mice when implanted subcutaneously. 
Mac2A, Sez4 and SeAx cells failed to produce tumors 
on multiple attempts, while PB2B sporadically produced 
small tumors in 2/6 implantation attempts that were heavily 
infiltrated by polymorphonuclear leukocytes. Other 8 cell 
lines reliably produced subcutaneous tumors. Interestingly, 
MyLa and HH MF lines as well as H9 and Hut78 Sézary 
Figure 2: Individual gene expression findings for Th1 cytokines (IFNG, IL-12A), T reg cytokine (IL-10), CD30 and 
advanced disease/poor prognosis genes (ITK, AHI1 and TRAF3IP3) in 11 patient-derived cell lines. (A-C) CTCL 
favorable prognosis genes IFNG, IL12A and SERPINB13 mRNA expression. (D-H) Poor prognosis genes CD30, IL-10, 
ITK, AHI1 and TRAF3IP3 expression.
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cells were most aggressive and produced sizable tumors 
within 2-4 weeks post implantation. Interestingly, SZ4, but 
not Sez4 cells also produced smaller tumors and at week 
4 these mice had to be euthanized as they were found 
to be piloerected and barbed. Hut102 and MJ cells too 
produced measurable tumors, but only 7-9 weeks after the 
implantation of these cells.
The obtained xenograft tumors were analyzed in 
a similar way as human CTCL skin biopsy specimens. 
We performed Hematoxylin and Eosin (H&E) staining 
of the tumors, immunophenotyping based on CD3, 
CD4, CD5, CD7, CD8, CD30 and CD45 RO staining 
(Figure 4B) and T cell receptor (TCR) clonality studies 
using PCR (Table 4). H&E staining in all cases revealed 
atypical lymphocytes with many mitotic figures. All cells 
stained positive for CD4 and only HTLV-1+ cells had a 
concomitant positive staining for CD8. CD7 pan T cell 
marker expression was lost in all tumors, while CD3 
and CD5 demonstrated variable expression patterns 
(Figure 4B). CD5 was expressed in all cells, while CD3 
was not expressed in MyLa and PB2B cells and stained 
only occasional cells in Hut102 tumors. Other cells 
demonstrated moderate-to-strong CD3 staining (Figure 
4B). CD30 was expressed in all cells. Notably PB2B 
tumors had regional/clonal expression pattern of this 
genes as islands of cells did not express CD30. CD45RO, 
a memory T cell marker, was also strongly expressed in all 
cell lines, as expected (Figure 4B).
TCR gene rearrangement studies on these xenograft 
tumors documented that all tissues were derived from 
clonal events (Table 4). The RT-PCR analysis documented 
TCR gamma chain was clonal in all cell lines that 
produced tumors and in addition to that the TCR beta 
chain was also clonal in HH, Hut78 and H9 cells (Table 4).
Figure 3: (A-D) Individual gene expression findings for advanced disease/poor prognosis genes (KIT, FYB, LCK, TBX3) 
and (E) cancer-testis poor prognosis gene GTSF1 in 11 patient-derived cell lines.
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Figure 4: Evaluating the ability of patient-derived CTCL cell lines to produce xenograft tumors in NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ mice. (A) Tumor growth measurements for 11 cell lines. Note, SZ4 mice had to be euthanized because they were barbed and 
piloerected even though the tumors did not reach 1 cm3 in volume. PB2B cells produced very small tumors that were heavily infiltrated by 
polymorphonuclear leukocytes. Sez4, SeAx and Mac2A cells did not produce tumors on multiple implantation attempts. (B) Hematoxylin 
and eosin staining of the obtained tissues and immunohistochemical characterization of these tumors based on pan T-cell marker expression 
(CD3, CD5, CD7); CD4 vs. CD8 expression; CD30 (advanced disease) and CD45RO (memory T-cell) marker expression.
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DISCUSSION
While the HTLV-1 viruses and their ability to 
cause ATLL was discovered in 1980’s, still today, the 
controversy ensues whether HTLV-1 plays any role in 
the pathogenesis of MF/SS even in the smallest subset 
of patients from HTLV-1 endemic regions. Furthermore, 
critical biological differences between HTLV-1-driven 
ATLL and classic MF/SS variants of CTCL remain poorly 
defined. This study for the first time highlights robust 
critical molecular differences between HTLV-1+ patient-
derived MJ and Hut102 cells that represent ATLL and 
classic HTLV-1- MF/SS cells. Consistent with the well-
described clinical observation for leukemic ATLL, these 
cells behave like advanced stage IV MF/SS cancers with 
respect to gene expression profiling and ability to produce 
tumors in mice. Furthermore, immunohistochemical 
analyses of cluster differentiation expression markers and 
TCR clonality studies in these tumors fall well within the 
expected range for the advanced MF/SS disease. Also, 
even though these cells showed lower sensitivity to HDAC 
inhibitors, their responses to tested medications were 
comparable to advanced MF/SS cells.
However, most importantly, the karyotype of 
these cells documented only minimal number of non-
specific chromosomal alterations and these cells were 
mostly diploid. These findings are consistent with the 
small numbers of chromosomal abnormalities that 
were reported in ATLL patients [29, 30]. Also, a 10q24 
leukemic chromosomal aberration, common in MF/SS, 
was characteristically absent in these cells.
Hence, like horses and zebras HTLV-1+ leukemia 
cells and SS/leukemic MF cells look similar despite 
having a very different genetic composition/origin. 
This work highlights that the lack of multiple structural 
abnormalities (including the commonly seen 10q24 
aberration) is a important difference between ATLL 
and classic MF/SS lymphomas that could be used as an 
important diagnostic test in these patients. In addition, 
our results indicate that HTLV-1 virus is not involved in 
the pathogenesis of classic MF/SS since, as exemplified 
by the MJ/Hut102 cells, this virus drives a very different 
pathway of lymphomagenesis that does not lead to an 
accumulation of a substantial number of chromosomal 
alterations and, hence, produces a very different cancer on 
a genetic/chromosomal level. Hence, detection of HTLV-1+ 
serology in any patient should alert a physician that they 
are dealing with a fundamentally different cancer than the 
classic MF/SS irrespective of their clinical presentation 
and disease course.
In this study we also performed a comprehensive 
comparison and characterization of the available 9 classic 
MF/SS cell lines. Many researchers in the field use these 
cells and, unfortunately, often their choice of cells is driven 
by availability as opposed to understanding what diseases 
these cell lines truly represent. While some skeptics see 
limited value in these cells, our work highlights that these 
cell lines, in fact, do represent typical MF/SS patients. 
They represent classic karyotypic and gene expression 
heterogenetiy that is seen in MF/SS cancers. This is 
especially exemplified by the comparison of karyotype 
changes that were observed in the 9 studied cell lines when 
compared to MF/SS patients (Supplementary Table 4). On 
the molecular level they show similar gene expression 
patterns that we and others have extensively documented 
in advanced MF/SS patients [44-47, 50, 54]. As seen in a 
subset of advanced CTCL patients, a number of these cells 
carry deleterious TP53 gene mutations. They also show 
heterogeneity of clinical responsiveness to Bexarotene and 
HDAC inhibitors that is commonly observed in advanced 
MF/SS disease. Importantly, a number of these cells are 
aggressive enough to produce tumors in NSG mice and 
these tumors show cluster differentiation marker staining 
results that are typically seen in classic MF/SS tumors.
We wish to highlight one important limitation 
in relation to these and other immortalized cancer cell 
lines. While the presented findings appear to be robust, 
it is always important to consider that molecular changes 
can differ in cell lines based on their passage number and 
culturing conditions.
In this work we further clarified that Sez4 and 
SZ4 genetically represent the same cell line. We also 
confirmed that the same malignant clone caused skin 
lesions in the patient that gave rise to Mac2A and PB2B 
cells. We validated that H9 and Hut78 cells represent the 
same clinical case/event, as expected. Importantly, based 
on our combined results presented in this paper, these 
9 cell lines are only suitable to study advanced MF/SS 
disease stages. None of these cell lines represent early 
stage (≤IIA) mycosis fungoides. Notably, MyLa represent 
advanced skin MF, Mac2A/PB2B represent advanced skin 
CD30+ MF/ALCL, while HH represent leukemic CD30+ 
MF. SeAx, Sez4/SZ4 and Hut78/H9 represent true Sézary 
Syndrome. Hence, based on this study, researchers should 
use appropriate cell lines in their clinical/translational 
investigations.
In conclusion, this work highlights key genetic/
biologic similarities and differences between HTLV-
1+ and HTLV-1- CTCL variants and provides extensive 
characterization for these 11 cell lines and places them in 
the context of the clinical spectrum for CTCL disease.
MATERIALS AND METHODS
Cell lines and culture/treatment conditions
HH, H9, Hut78, MJ and Hut102 patient-derived 
CTCL cell lines were previously described [55, 56] 
and were purchased from the American Tissue Culture 
Collection (ATCC). H9 is a clonal derivative of Hut78 cell 
line [57]. MyLa, PB2B, Mac2A, SZ4, SeAx, Sez4 were 
a generous gift from professors K. Kaltoft and N. Ødum 
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(Copenhagen, Denmark) and were initially described 
elsewhere [31, 58-61]. Detailed summary of cell lines is 
provided in Supplementary Table 1. MJ, Hut78 cells were 
serially passaged in IMDM media (Invitrogen) containing 
20% and 10% fetal bovine serum, respectively (FBS) 
(Invitrogen). HH, H9, Hut102, MyLa, Mac2A and SZ4 
cells were grown in RPMI media containing 10% FBS. 
Finally, Sez4 and SeAx cells were grown in RPMI media 
containing 10% FBS, 5 ng/mL of recombinant human IL-2 
and IL-4 (R&D Systems, Minneapolis, MN). All cells 
were grown in 5% CO2, 95% air humidified incubator at 
37oC.
To inhibit histone deacetylase (HDAC) activity cells 
were treated with 0-40 μM of Suberoylanilide Hydroxamic 
Acid (SAHA also known as Vorinostat, Santa Cruz, Dallas, 
TX) or 0-4μM Romidepsin (Adooq Bioscience, Irvine 
CA). Cells were also treated with 0-40μM of Bexarotene 
(Santa Cruz Biotechnology, Dallas, TX).
Quantitative RT-PCR analysis of gene 
expression
mRNA from cell lines was isolated using a Quiagen 
kit (Valencia, CA) and was converted into cDNA using 
Bio-Rad iScript cDNA synthesis kit. Gene expression on 
mRNA level was evaluated using quantitative RT-PCR as 
previously described [18, 19, 20, 43-45]. We have tested 
107 genes that were studied and described in our prior 
work on CTCL patients [44, 50]. Primer pair sequences 
for the tested genes and control housekeeping genes are 
listed in Supplementary Table 5. Primer pairs for Tax, 
Gag, Pol, Env and pX HTLV-1 genes are also listed in 
Supplementary Table 5. The expression was standardized 
using genorm method [62] utilizing ACTB, SDHA and 
YWHAZ housekeeping genes. Gene expression in MJ cells 
was set as 1 fold similarly to the protocol in our previous 
studies [20, 45]. MJ cell line was selected as reference, 
since all genes showed detectable expression in this line. 
qRT-PCR relative expression was transformed as base-2 
log of the ratio against MJ cells, independently for each 
gene. These log2-ratio data points were hierarchically 
clustered (euclidian distance, complete linkage) using 
both genes and cell lines as observation points to obtain 
two dendrograms. The log2-ratio data matrix is shown as 
a heatmap where rows (genes) and columns (cell lines) 
are ordered to match the respective dendrogram. Data 
and figures generated using the R project for statistical 
computing (https://www.r-project.org).
G band and spectral karyotyping, TP53 
sequencing and MTT cell survival analyses
G-band and spectral karyotyping of chromosomes 
was performed in our laboratory and by The Centre for 
Applied Genomics, The Hospital for Sick Children 
(Toronto, ON) as previously described [63].
TP53 sequencing was performed by the Molecular 
Genetics Laboratory, The Hospital For Sick Children 
(Toronto, ON) as previously described [64, 65]. MTT 
assay reagents were obtained from Sigma-Aldrich and 
were performed as previously described [66]. Briefly, 
standard curves were generated for each cell line to enable 
conversion from absorbance to cell number values. To 
obtain IC50 values, cells were plated in 96 well plates and 
treated for 24 hours using respective concentrations of 
SAHA (i.e, Vorinostat), Romidepsin and Bexarotene and 
percent kill was determined using standard MTT protocol.
Xenograft model of CTCL
The University of Ottawa Animal Care and Ethics 
Committee approved all experimental procedures involving 
the xenograft experiments on the immunodeficient NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ (also commonly referred to as 
NSG) strain of mice (Jackson Laboratory, Bar Harbor, 
ME). These mice lack mature T cells, B cells or functional 
NK cells and are deficient in cytokine signaling. The CTCL 
cell lines Myla, Mac2a, PB2B, HH, H9, Hut78, SZ4, Sez4, 
SeAx, MJ and Hut102 were harvested individually from 
tissue culture, pelleted and re-suspended in DPBS (Corning, 
Manassas, VA). Eight week old female mice were injected 
subcutaneously (s.c) with 2.5x106 cells suspended in a total 
volume of 200μl of sterile DPBS into the two hind flanks. 
Mice were housed with enrichment in groups of 4 in a 
biohazard facility. The condition of the mice was monitored 
daily for the first 48 hours post injection. Tumor onset 
and growth was then assessed on a weekly basis by flank 
palpation within a biosafety cabinet under aseptic conditions. 
As the tumors progressed, they were measured by slide 
calipers and recorded over the course of 9 weeks. When 
tumor progression neared the endpoint volume of 1cm3, the 
animals were monitored daily. At experiment termination 
or wellness endpoint, the mice were euthanized by CO2 
followed by cervical dislocation and tumors were excised, 
measured and weighed.
Tissue processing, Hematoxylin and Eosin (H&E) 
staining, immunohistochemical analyses for CD3, CD4, 
CD5, CD7, CD8, CD30, CD45RO expression and TCR 
clonality analyses were subsequently performed on the 
formalin-fixed tumors as per standard clinical protocols in 
our hospital as previously described [67].
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